news1The new company, Atlas Molecular Pharma, will further develop its proprietary technology to act as a “drug discovery engine” for the discovery and development of drugs called pharmacological chaperones, which act by restoring defective protein activity – this is a common pathological mechanism which Atlas will target, and is present in around 80% of the 7,000 Rare and Ultra-Rare diseases described to date that are caused by genetic mutations which affect protein stability and activity.

The initial focus of Atlas Molecular Pharma will be in discovering and developing treatments for Congenital Erythropoietic Porphyria and Creutzfeldt-Jakob disease (a prion disease).

See details here.